Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Nicotinamide (niacinamide) is the amide form of vitamin B3 that serves as a precursor to NAD+ and NADP+, coenzymes critical for DNA repair, energy metabolism, and cellular signaling. Unlike nicotinic acid, it does not activate GPR109A receptors, so it delivers therapeutic effects without causing skin flushing.
Origin & History
Nicotinamide (niacinamide) is the amide form of vitamin B3, a water-soluble vitamin essential for cellular metabolism. It is produced synthetically or derived from natural sources like yeast, bacteria, or animal tissues through chemical amidation of nicotinic acid. Chemically belonging to the pyridine carboxamide class, it serves as a precursor to NAD+, a critical coenzyme in redox reactions.
Research Narrative (Provisional)
The landmark ONTRAC Phase 3 RCT (PMID: 26488693) demonstrated nicotinamide's efficacy in 386 high-risk patients, showing 23% reduction in new non-melanoma skin cancers. A meta-analysis (PMID: 37994989) pooled 4 RCTs but found mixed results, with clearer benefits for squamous cell carcinoma prevention. A pilot study in kidney transplant recipients (PMID: 37838527) showed limited efficacy with tolerability issues at higher doses.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Nicotinamide (niacinamide) is the amide form of vitamin B3 (niacin), with a molecular weight of 122.12 g/mol. It is a water-soluble vitamin that serves as the precursor to nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+), two critical coenzymes involved in over 400 enzymatic reactions. Standard supplemental doses range from 500 mg to 1500 mg/day (typically 500 mg twice or thrice daily for skin cancer chemoprevention). Oral bioavailability is high (~100%), rapidly absorbed in the small intestine, with peak plasma levels reached within 1-2 hours. Unlike nicotinic acid, nicotinamide does not cause flushing at therapeutic doses. It contains no macronutrients, fiber, or minerals—it is a pure bioactive compound. Hepatic metabolism converts nicotinamide to NAD+ via the salvage pathway enzyme nicotinamide phosphoribosyltransferase (NAMPT). Excess is methylated to N-methyl-nicotinamide and further oxidized metabolites excreted renally. Dietary sources include poultry (~12 mg/100g), tuna (~8.6 mg/100g), beef liver (~16 mg/100g), and fortified cereals, though chemoprevention doses far exceed dietary intake (~15-20 mg NE RDA).
Reported Mechanism (Provisional)
Nicotinamide is converted intracellularly to NAD+ via the salvage pathway, where nicotinamide phosphoribosyltransferase (NAMPT) catalyzes its conversion to nicotinamide mononucleotide (NMN), which is subsequently adenylated by NMNAT enzymes. Elevated NAD+ activates PARP-1 and PARP-2, enzymes that repair UV-induced DNA strand breaks, and also fuels sirtuins (SIRT1–SIRT7), deacetylases that regulate inflammation and genomic stability. Additionally, nicotinamide inhibits poly-ADP-ribose polymerase overactivation that would otherwise deplete NAD+ stores during oxidative stress, preserving cellular energy reserves.
Clinical Narrative (Provisional)
The strongest evidence comes from a Phase 3 RCT (n=386, PMID: 26488693) in high-risk patients, demonstrating that 500 mg twice-daily oral nicotinamide reduced new non-melanoma skin cancers by 23%, actinic keratoses by 11–20%, and squamous cell carcinoma incidence by approximately 30% over 12 months compared to placebo. These benefits disappeared within 6 months of discontinuation, indicating the effect requires sustained supplementation. Dermatological evidence is rated strong given the double-blind, placebo-controlled design and clinically meaningful effect sizes. Evidence for other proposed benefits — including glucose metabolism, inflammatory skin conditions, and osteoarthritis — is generally rated moderate to weak, drawn from smaller or shorter trials with less consistent outcomes.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.